```
$%^STN;HighlightOn=  ***;HighlightOff=***  ;

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1635KXH

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS  4  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS  5  FEB 05   German (DE) application and patent publication number format
                   changes
 NEWS  6  MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03   FRANCEPAT now available on STN
 NEWS  9  MAR 29   Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29   WPIFV now available on STN
 NEWS 11  MAR 29   New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 12  APR 26   PROMT: New display field available
 NEWS 13  APR 26   IFIPAT/IFIUDB/IFICDB: New super search and display field
                   available
 NEWS 14  APR 26   LITALERT now available on STN
 NEWS 15  APR 27   NLDB: New search and display fields available
 NEWS 16  May 10   PROUSDDR now available on STN
 NEWS 17  May 19   PROUSDDR: One FREE connect hour, per account, in both May
                   and June 2004
 NEWS 18  May 12   EXTEND option available in structure searching
 NEWS 19  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 20  May 17   FRFULL now available on STN
 NEWS 21  May 27   STN User Update to be held June 7 and June 8 at the SLA 2004
                   Conference
 NEWS 22  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS 23  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS 24  May 27   Explore APOLLIT with free connect time in June 2004

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:55:07 ON 08 JUN 2004

=> s cytomegalovirus or (herpes simplex) or (varicellar)
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
```

```
=> b medline caplus lifesci embase uspatfull biosis
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.42       0.42

FILE 'MEDLINE' ENTERED AT 12:56:01 ON 08 JUN 2004

FILE 'CAPLUS' ENTERED AT 12:56:01 ON 08 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 12:56:01 ON 08 JUN 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 12:56:01 ON 08 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 12:56:01 ON 08 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:56:01 ON 08 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s cytomegalovirus or (herpes simplex) or (varicellar)
L1      235427 CYTOMEGALOVIRUS OR (HERPES SIMPLEX) OR (VARICELLAR)

=> s l1 and (calpain or e64D) or (z()leu()leu()h)
L2          340 L1 AND (CALPAIN OR E64D) OR (Z(W) LEU(W) LEU(W) H)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3           323 DUP REM L2 (17 DUPLICATES REMOVED)

=> s l1 and ((calpain or e64D) or (z()leu()leu()h))
L4          335 L1 AND ((CALPAIN OR E64D) OR (Z(W) LEU(W) LEU(W) H))

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5           321 DUP REM L4 (14 DUPLICATES REMOVED)

=> s l5 and PY<2000
   3 FILES SEARCHED...
L6           26 L5 AND PY<2000

=> d l6 ibib abs tot

L6   ANSWER 1 OF 26  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         1999:723196  CAPLUS
DOCUMENT NUMBER:          131:333006
TITLE:                    Production of recombinant replication-deficient viral
                          vectors encoding exogenous transgenes via
                          microcarrier-based process
INVENTOR(S):              Giroux, Daniel D.; Goudreau, Ann M.; Ramachandra,
                          Muralidhara; Shabram, Paul W.
PATENT ASSIGNEE(S):       Canji, Inc., USA
SOURCE:                   PCT Int. Appl., 32 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

      PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
      ---------------   ----  --------       ---------------   --------
      WO 9957297         A1   19991111       WO 1999-US9813    19990504 <--
          W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE,
              DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR,
              KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT,
              RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA,
              AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
              ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
              CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      US 5994134         A    19991130       US 1998-73076     19980504 <--
```



AU 9938823	A1	19991123	AU 1999-38823	19990504	<--
EP 1078095	A1	20010228	EP 1999-921681	19990504	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO					
JP 2002513583	T2	20020514	JP 2000-547250	19990504	
PRIORITY APPLN. INFO.:			US 1998-73076	A 19980504	
			WO 1999-US9813	W 19990504	

AB The present invention is directed to a method of producing recombinant viral vectors at high titers incorporating a variety of important advancements over the art. The method of the present invention incorporates multiple features which provide enhanced prodn. of viruses, particularly those viruses encoding exogenous transgenes. The specifically illustrated method describes a method for the high titer serum-free media prodn. of recombinant replication defective adenoviruses contg. an exogenous transgene. The invention provides methods of prepg. microcarriers, methods for seeding bioreactors at high cell d., increasing the infectivity of the producer cells to the virus, methods to increase product yield through synchronization of the cell cycle of the producer cells, and methods to minimize the deleterious effects of exogenous transgenes. The invention further provides producer cells prepd. by the process of the invention. The invention further provides viruses produced by the process.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:718875 CAPLUS
DOCUMENT NUMBER: 131:348774
TITLE: Tandem fluorescent protein constructs and their preparation for enzyme assays
INVENTOR(S): Tsien, Roger Y.; Heim, Roger; Cubitt, Andrew
PATENT ASSIGNEE(S): The Regents of the University of California, USA; Aurora Biosciences Corporation
SOURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 594,575. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5981200	A	19991109	US 1997-792553	19970131	<--
PT 877805	T	20021031	PT 1997-905667	19970131	
ES 2177939	T3	20021216	ES 1997-905667	19970131	
US 2003186229	A1	20031002	US 2001-865291	20010524	
US 2002164674	A1	20021107	US 2002-57505	20020125	
PRIORITY APPLN. INFO.:			US 1996-594575	A2 19960131	
			US 1997-792553	A1 19970131	
			US 1999-396003	B2 19990913	

AB This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymic assays. Mutant green fluorescent proteins (GFPs) were created by mutagenesis of the Aequorea victoria GFP. Polyhistidine tagged tandem green and blue fluorescent proteins were recombinantly constructed having an inserted peptide sequence including cleavage recognition sites for many proteases. Cleavage expts. were done with trypsin, enterokinase and ***calpain*** .

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:728567 CAPLUS
DOCUMENT NUMBER: 130:10614
TITLE: Ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections
ENTOR(S): Borgford, Thor
T ASSIGNEE(S): De Novo Enzyme Corp., Can.
PCT Int. Appl., 352 pp.
CODEN: PIXXD2
YPE: Patent
English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9849311	A2	19981105	WO 1998-CA394	19980430	<--
WO 9849311	A3	19990211			

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9870237	A1	19981124	AU 1998-70237	19980430	<--
EP 977862	A2	20000209	EP 1998-916743	19980430	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2001523961	T2	20011127	JP 1998-546437	19980430	
US 6593132	B1	20030715	US 1999-403752	19991029	
US 2004009551	A1	20040115	US 2003-394511	20030324	

PRIORITY APPLN. INFO.:	US 1997-45148P	P	19970430
	US 1997-63715P	P	19971029
	WO 1998-CA394	W	19980430
	US 1999-403752	A3	19991029

AB Ricin precursors with the ricin A and B chains linked by a protease-labile linker peptide are described for use in the treatment of disease. The linker peptide contains a cleavage site for a disease specific protease such as a cancer, fungal, viral or parasitic protease. The ricin A chain may be replaced by comparable cytotoxic proteins such as the abrin A chain. The protein is delivered to the target tissue using viral vectors carrying an expression cassette for the ricin fusion protein gene. Construction of a series of variants of preproricin cleavable by a no. of different proteinases is described. Cleavage and activation of these variants with the expected patterns of cleavage of rRNA is demonstrated.

L6 ANSWER 4 OF 26 USPATFULL on STN

ACCESSION NUMBER:	2003:296940 USPATFULL
TITLE:	Lactacystin analogs
INVENTOR(S):	Schreiber, Stuart L., Boston, MA, United States Standaert, Robert F., Bryan, TX, United States Fenteany, Gabriel, Cambridge, MA, United States Jamison, Timothy F., Cambridge, MA, United States
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6645999	B1	20031111	
	WO 9632105		19961017	<--
APPLICATION INFO.:	US 1997-945092		19970126	(8)
	WO 1996-US5072		19960412	
			19980126	PCT 371 date

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-421583, filed on 12 Apr 1995
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Travers, Russell
LEGAL REPRESENTATIVE:	Hale and Dorr LLP
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	2868

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds related to lactacystin and lactacystin Beta-lactone, pharmaceutical compositions containing the compounds, and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 26 USPATFULL on STN

ACCESSION NUMBER:	2003:190684 USPATFULL
TITLE:	Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
INVENTOR(S):	Borgford, Thor, Burnaby, CANADA
PATENT ASSIGNEE(S):	Twinstrand Therapeutics Inc., Vancouver, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6593132	B1	20030715	
	WO 9849311		19981105	<--
APPLICATION INFO.:	US 1999-403752		19991029	(9)
	WO 1998-CA394		19980430	

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Bereskin & Parr, Gravelle, Micheline
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 254 Drawing Figure(s); 254 Drawing Page(s)
LINE COUNT: 5176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a cancer, fungal, viral or parasitic protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cancer cells, cells infected with a virus, a fungus, or parasite, or parasites utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human cancer, viral infection, fungal infection, or parasitic infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 26 USPATFULL on STN
ACCESSION NUMBER: 2002:115819 USPATFULL
TITLE: Fibrinogen-coated particles for therapeutic use
INVENTOR(S): Yen, Richard C. K., Yorba Linda, CA, United States
PATENT ASSIGNEE(S): Hemosphere, Inc., Anaheim, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6391343	B1	20020521	
	WO 9639128		19961212	<--
APPLICATION INFO.:	US 1998-952765		19980410	(8)
	WO 1996-US9458		19960604	
			19980410	PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-554919, filed on 9 Nov 1995, now abandoned Continuation-in-part of Ser. No. US 1995-471650, filed on 6 Jun 1995, now patented, Pat. No. US 5725804 Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 Continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of soluble fibrinogen not capable by it self of formation of a clot upon activation by thrombin.

AS INDEXING IS AVAILABLE FOR THIS PATENT.

6 ANSWER 7 OF 26 USPATFULL on STN
CCESSION NUMBER: 2001:82299 USPATFULL
ITLE: Method and product for cleaning and/or whitening of

VENTOR(S): Rinne, Ari, Pajutie 3 B, FIN-2G900 Turku, Finland

	NUMBER	KIND	DATE	
TENT INFORMATION:	US 6241973	B1	20010605	
	WO 9829088		19980709	<--
PLICATION INFO.:	US 1999-331777		19990624	(9)
	WO 1998-FI1		19980102	
			19990624	PCT 371 date
			19990624	PCT 102(e) date

	NUMBER	DATE
IORITY INFORMATION:	FI 1997-12	19970103

CUMENT TYPE: Utility
LE SEGMENT: Granted
IMARY EXAMINER: Rose, Shep K.
GAL REPRESENTATIVE: Lydon, James C.
MBER OF CLAIMS: 12
EMPLARY CLAIM: 1
NE COUNT: 583
S INDEXING IS AVAILABLE FOR THIS PATENT.

A method and a product for cleaning and/or whitening of teeth. Natural human cysteine proteinases are employed for cleaning and whitening purposes and this activity can be blocked by natural cysteine protease inhibitors, which are released secondarily from the product at a later stage. The use of natural cysteine proteinases and their inhibitors provides the advantage that they are man's own proteins, and therefore the risk of allegorization is minimized. In addition, their enzyme kinetics are will known.

S INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 8 OF 26 USPATFULL on STN
CESSION NUMBER: 2000:41033 USPATFULL
TLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
VENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Doctrow, Susan Robin, Roslindale, MA, United States
TENT ASSIGNEE(S): Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
TENT INFORMATION:	US 6046188		20000404	
	WO 9640148		19961219	<--
PLICATION INFO.:	US 1998-973577		19980311	(8)
	WO 1996-US10037		19960606	
			19980311	PCT 371 date
			19980311	PCT 102(e) date

LATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-485489, filed on 7 Jun 1995, now patented, Pat. No. US 5696109
CUMENT TYPE: Utility
LE SEGMENT: Granted
IMARY EXAMINER: Reamer, James H.
GAL REPRESENTATIVE: Townsend & Townsend & Crew LLP
MBER OF CLAIMS: 24
EMPLARY CLAIM: 1
MBER OF DRAWINGS: 28 Drawing Figure(s); 16 Drawing Page(s)
NE COUNT: 3405
S INDEXING IS AVAILABLE FOR THIS PATENT.

The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds.

S INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 9 OF 26 USPATFULL on STN
CESSION NUMBER: 1999:166974 USPATFULL
TLE: Cysteine protease inhibitors
VENTOR(S): Spruce, Lyle W., Chula Vista, CA, United States
Gyorkos, Albert C., Westminster, CO, United States

Goodfellow, Val S., Tucson, AZ, United States
Leimer, Axel H., Westborough, MA, United States
Young, John M., Redwood City, CA, United States
Gerrity, James Ivan, Albany, OR, United States
PATENT ASSIGNEE(S): Cortech Inc., Bedminster, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6004933		19991221	<--
APPLICATION INFO.:	US 1998-65258		19980423	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-44819P	19970425 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Solola, Taofiq A.
LEGAL REPRESENTATIVE: Dechert Price & Rhoads
NUMBER OF CLAIMS: 146
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to cysteine protease inhibitors of the general formula (I): ##STR1## wherein Z is a cysteine protease binding moiety; X and Y are S, O or optionally substituted N; and R.sub.1 is optionally substituted alkyl or aryl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1999:155518 USPATFULL
TITLE: Viral production process
INVENTOR(S): Giroux, Daniel D., La Jolla, CA, United States
Goudreau, Ann M., San Diego, CA, United States
Ramachandra, Muralidhara, San Diego, CA, United States
Shabram, Paul W., Olivenhain, CA, United States
PATENT ASSIGNEE(S): Canji, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5994134		19991130	<--
APPLICATION INFO.:	US 1998-73076		19980504	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Murphy, Richard B.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a method of producing recombinant viral vectors at high titers incorporating a variety of important advancements over the art. The method of the present invention incorporates multiple features which provide enhanced production of viruses, particularly those viruses encoding exogenous transgenes. The specifically illustrated method describes a method for the high titer serum-free media production of recombinant replication defective adenoviruses containing an exogenous transgene. The invention provides methods of preparing microcarriers, methods for seeding bioreactors at high cell density, increasing the infectivity of the producer cells to the virus, methods to increase product yield through synchronization of the cell cycle of the producer cells, and methods to minimize the deleterious effects of exogenous transgenes. The invention further provides producer cells prepared by the process of the invention. The invention further provides viruses produced by the process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1999:137014 USPATFULL
TITLE: Vesicle transport related protein

Corley, Neil C., Mountain View, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5976865		19991102	<--
APPLICATION INFO.:	US 1997-984172		19971203	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Incyte Pharmaceuticals, Inc.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a human vesicle transport related protein (VTRP) and polynucleotides which identify and encode VTRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of VTRP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1999:102423 USPATFULL
TITLE: Method for making non-crosslinked protein particles for therapeutic and diagnostic use
INVENTOR(S): Yen, Richard C. K., Glendora, CA, United States
PATENT ASSIGNEE(S): Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5945033		19990831	<--
APPLICATION INFO.:	US 1996-747137		19961112	(8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 which is a continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 3655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of hemoglobin in the particle composition. Particles which are primarily hemoglobin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against aggregation by the incorporation of either albumin, surface active agents or gelatin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1999:81758 USPATFULL
TITLE: Non-activated receptor complex proteins and uses thereof
INVENTOR(S): Davis, Roger J., Princeton, MA, United States
Galcheva-Gargova, Zoya, Worcester, MA, United States
PATENT ASSIGNEE(S): University of Massachusetts, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5925566		19990720	<--

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-19219P	19960606 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campell, Bruce R.
ASSISTANT EXAMINER: Nguyen, Dave Trong
LEGAL REPRESENTATIVE: Fish & Richardson, P.C.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 2438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a substantially pure ZPR1 polypeptide. For example, a ZPR1 polypeptide that specifically binds to a non-activated membrane-bound receptor (e.g., EGF or PDGF receptors) and specifically binds small nucleolar RNAs (e.g., U3). ZPR1 polypeptides can be isolated from any eukaryote, including mammals (e.g. rodents and humans) and fungi (e.g., S. cerevisiae and S. pombe).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1999:36949 USPATFULL
TITLE: Engineering oral tissues
INVENTOR(S): Mooney, David J., Ann Arbor, MI, United States
Rutherford, Robert B., Ann Arbor, MI, United States
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5885829		19990323	<--
APPLICATION INFO.:	US 1997-864494		19970528	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-18450P	19960528 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 109
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 8001
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for regenerating dental and oral tissues from viable cells using ex vivo culture on a structural matrix. The regenerated oral tissues and tissue-matrix preparations thus provided have both clinical applications in dentistry and oral medicine and are also useful in in vitro toxicity and biocompatibility testing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1998:138941 USPATFULL
TITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
INVENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Doctrow, Susan Robin, Roslindale, MA, United States
PATENT ASSIGNEE(S): Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5834509		19981110	<--
APPLICATION INFO.:	US 1995-479697		19950607	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-380731, filed on 26 Jan 1995 which is a continuation-in-part of Ser. No. US 1992-987474, filed on 7 Dec 1992, now patented, Pat. No. US 5403834

	NUMBER	DATE

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides salen-manganese complexes and pharmaceutically acceptable compositions thereof useful as antioxidants and free radical scavengers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1998:134999 USPATFULL
TITLE: Methods for the treatment of bone resorption disorders, including osteoporosis
INVENTOR(S): Gelb, Bruce D., Dobbs Ferry, NY, United States
Chapman, Harold, Newton, MA, United States
Desnick, Robert J., New York, NY, United States
PATENT ASSIGNEE(S): Mount Sinai School of Medicine of the City of New York, New York, NY, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5830850		19981103	<--
APPLICATION INFO.:	US 1996-704473		19960828	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for the amelioration of symptoms caused by bone resorption disorders, including but not limited to osteoporosis, arthritides and periodontal disease, and damage caused by macrophage-mediated inflammatory processes. In one embodiment, the methods and compositions of the invention include methods and compositions for the specific inhibition of cathepsin K activity. In an additional embodiment, the methods and compositions of the invention include methods and compositions for the specific inhibition of cathepsin K activity coupled with specific inhibition of at least a second activity involved in the bone resorption and/or macrophage-mediated inflammatory processes. In a particular embodiment, the methods and compositions of the invention include methods and compositions for the specific inhibition of cathepsin K and cathepsin S activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1998:131743 USPATFULL
TITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
INVENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Doctrow, Susan Robin, Roslindale, MA, United States
PATENT ASSIGNEE(S): Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5827880		19981027	<--
APPLICATION INFO.:	US 1995-380731		19950126	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-987474, filed on 7 Dec 1992, now patented, Pat. No. US 5403834
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nazario-Gonzalez, Porfirio
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

EXEMPLARY CLAIM: 1,12
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1998:58182 USPATFULL
TITLE: Lactacystin analogs
INVENTOR(S): Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5756764		19980526	<--
APPLICATION INFO.:	US 1995-466468		19950606 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1995-421583, filed on 12 Apr 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Stockton, Laura L.
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 2392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are compounds related to lactacystin and lactacystin .beta.-lactone, pharmaceutical compositions containing the compounds, and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1998:57716 USPATFULL
TITLE: Aptamers specific for biomolecules and methods of making
INVENTOR(S): Griffin, Linda, Atherton, CA, United States
Albrecht, Glenn, Redwood City, CA, United States
Latham, John, Palo Alto, CA, United States
Leung, Lawrence, Hillsborough, CA, United States
Vermaas, Eric, Oakland, CA, United States
Toole, John J., Burlingame, CA, United States
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5756291		19980526	<--
APPLICATION INFO.:	US 1995-484192		19950607 (8)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-934387, filed on 21 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Bosse, Mark L.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 8242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for identifying oligomer sequences, optionally comprising modified base, which specifically bind target molecules such as serum proteins, kinins, eicosanoids and extracellular proteins is described.

PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, PGF2 and cell surface molecules. The technique involves complexation of the target molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for therapeutic and diagnostic purposes and for generating secondary aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 26 USPATFULL on STN

ACCESSION NUMBER:	1998:24868 USPATFULL
TITLE:	Non-crosslinked protein particles for therapeutic and diagnostic use
INVENTOR(S):	Yen, Richard C. K., Yorba Linda, CA, United States
PATENT ASSIGNEE(S):	Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5725804		19980310	<--
APPLICATION INFO.:	US 1995-471650		19950606	(8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 which is a continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Lovering, Richard D.
LEGAL REPRESENTATIVE:	Townsend & Townsend & Crew
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
LINE COUNT:	2178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of a stabilizing agent in the particle composition. Particles which are primarily albumin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolublization by the incorporation of a reducing agent, oxidizing agent, hydrogen-accepting molecule, high molecular weight polymer, sulfur-containing ring compound or combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 26 USPATFULL on STN

ACCESSION NUMBER:	97:115268 USPATFULL
TITLE:	Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
INVENTOR(S):	Malfroy-Camine, Bernard, Arlington, MA, United States Doctrow, Susan Robin, Roslindale, MA, United States
PATENT ASSIGNEE(S):	Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5696109		19971209	<--
APPLICATION INFO.:	US 1995-485489		19950607	(8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-380731, filed on 26 Jan 1995 which is a continuation-in-part of Ser. No. US 1992-987474, filed on 7 Dec 1992, now patented, Pat. No. US 5403834

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1993-US11857	19931206

FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 26 USPATFULL on STN
ACCESSION NUMBER: 97:26904 USPATFULL
TITLE: Non-crosslinked protein particles for therapeutic and diagnostic use
INVENTOR(S): Yen, Richard C. K., Glendora, CA, United States
PATENT ASSIGNEE(S): Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5616311		19970401	<--
APPLICATION INFO.:	US 1994-212546		19940314	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Townsend & Townsend & Crew
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1,26
LINE COUNT: 2585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of hemoglobin in the particle composition. Particles which are primarily hemoglobin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against aggregation by the incorporation of either albumin, surface active agents or gelatin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 26 USPATFULL on STN
ACCESSION NUMBER: 95:29636 USPATFULL
TITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
INVENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Baudry, Michel, Long Beach, CA, United States
PATENT ASSIGNEE(S): Eukarion, Inc., Arlington, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5403834		19950404	<--
APPLICATION INFO.:	US 1992-987474		19921207	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Henley, III, Raymond
ASSISTANT EXAMINER: Criares, T. J.
LEGAL REPRESENTATIVE: Dunn, Tracy J.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 26 USPATFULL on STN
ACCESSION NUMBER: 94:51514 USPATFULL
TITLE: Antiplatelet and antithrombotic activity of platelet glycoprotein Ib receptor fragments
INVENTOR(S): Handin, Robert, Needham, MA, United States
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5321127		19940614	<--
APPLICATION INFO.:	US 1991-670606		19910318	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A platelet glycoprotein Ib receptor fragment, having antiplatelet and antithrombotic activity, useful for blocking platelet adhesion. The invention may be used in the treatment of patients who are particularly prone to thrombosis and embolism. The invention may also be used to purify von Willebrands factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1999:184941 BIOSIS
DOCUMENT NUMBER: PREV199900184941
TITLE: Human ***cytomegalovirus*** -activated ***calpain*** and p21Cip1 degradation in human lung fibroblasts.
AUTHOR(S): Chen, Z.; Knutson, E.; Kurosky, A.; Liu, S.; Albrecht, T.
CORPORATE SOURCE: Univ. Texas Med. Branch, Galveston, TX 77555, USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1999) Vol. 40, pp. 447-448. print.
Meeting Info.: 90th Annual Meeting of the American Association for Cancer Research. Philadelphia, Pennsylvania, USA. April 10-14, 1999. American Association for Cancer Research.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 5 May 1999
Last Updated on STN: 5 May 1999

L6 ANSWER 26 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1993:407472 BIOSIS
DOCUMENT NUMBER: PREV199396073197
TITLE: Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors.
AUTHOR(S): Molla, Akhteruzzaman; Hellen, Christopher U. T.; Wimmer, Eckard [Reprint author]
CORPORATE SOURCE: Dep. Microbiol., Sch. Med., State Univ. New York at Stony Brook, Stony Brook, NY 11794-8621, USA
SOURCE: Journal of Virology, (1993) Vol. 67, No. 8, pp. 4688-4695.
CODEN: JOVIAM. ISSN: 0022-538X.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Sep 1993
Last Updated on STN: 6 Nov 1993
AB A polyprotein cleavage assay has been developed to assay the proteolytic activities in vitro of the 2A proteinases encoded by poliovirus and human rhinovirus 14, which are representative members of the Enterovirus and Rhinovirus genera of picornaviruses, respectively. The elastase-specific substrate-based inhibitors elastatinal and methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone (MPCMK) inhibited both 2A proteinases in vitro. The

incubation with elastatinal, whereas the mobility of a Cys-109 fwdarw -Ala poliovirus 2A-pro mutant was unchanged, an observation suggesting that this inhibitor may have formed a covalent bond with the active-site Cys-109 nucleophile. Iodoacetamide, ***calpain*** inhibitor 1, and antipain inhibited poliovirus 2A-pro. MPCMK caused a reduction in the yields of the enteroviruses poliovirus type 1 and coxsackievirus A21 and of human rhinovirus 2 in infected HeLa cells but did not affect the growth of encephalomyocarditis virus, a picornavirus of the Cardiovirus genus. MPCMK abrogated the shutoff of host cell protein synthesis that is induced by enterovirus and rhinovirus infection and reduced the synthesis of virus-encoded polypeptides in infected cells. These results indicate that the determinants of substrate recognition by 2A proteinases resemble those of pancreatic and leukocyte elastases. These results may be relevant to the development of broad-range chemotherapeutic agents against entero- and rhinoviruses.

=> d l6 ibib kwic tot

L6 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:723196 CAPLUS
DOCUMENT NUMBER: 131:333006
TITLE: Production of recombinant replication-deficient viral vectors encoding exogenous transgenes via microcarrier-based process
INVENTOR(S): Giroux, Daniel D.; Goudreau, Ann M.; Ramachandra, Muralidhara; Shabram, Paul W.
PATENT ASSIGNEE(S): Canji, Inc., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9957297	A1	19991111	WO 1999-US9813	19990504	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 5994134	A	19991130	US 1998-73076	19980504	<--
CA 2328084	AA	19991111	CA 1999-2328084	19990504	<--
AU 9938823	A1	19991123	AU 1999-38823	19990504	<--
EP 1078095	A1	20010228	EP 1999-921681	19990504	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO					
JP 2002513583	T2	20020514	JP 2000-547250	19990504	

PRIORITY APPLN. INFO.: US 1998-73076 A 19980504
WO 1999-US9813 W 19990504

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 9957297 A1 ***19991111***

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 9957297	A1	19991111	WO 1999-US9813	19990504	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 5994134	A	19991130	US 1998-73076	19980504	<--
CA 2328084	AA	19991111	CA 1999-2328084	19990504	<--
AU 9938823	A1	19991123	AU 1999-38823	19990504	<--
EP 1078095	A1	20010228	EP 1999-921681	19990504	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO					
JP 2002513583	T2	20020514	JP 2000-547250	19990504	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(early, ***cytomegalovirus*** ; prodn. of recombinant replication-deficient viral vectors encoding exogenous transgenes via microcarrier-based process)

T 110044-82-1, ***Calpain*** inhibitor I
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(prodn. of recombinant replication-deficient viral vectors encoding exogenous transgenes via microcarrier-based process)

6 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2004 ACS on STN
CCESSION NUMBER: 1999:718875 CAPLUS
OCUMENT NUMBER: 131:348774
ITLE: Tandem fluorescent protein constructs and their preparation for enzyme assays
NVENTOR(S): Tsien, Roger Y.; Heim, Roger; Cubitt, Andrew
ATENT ASSIGNEE(S): The Regents of the University of California, USA; Aurora Biosciences Corporation
OURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 594,575.
CODEN: USXXAM
OCUMENT TYPE: Patent
ANGUAGE: English
AMILY ACC. NUM. COUNT: 4
ATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5981200	A	19991109	US 1997-792553	19970131 <--
PT 877805	T	20021031	PT 1997-905667	19970131
ES 2177939	T3	20021216	ES 1997-905667	19970131
US 2003186229	A1	20031002	US 2001-865291	20010524
US 2002164674	A1	20021107	US 2002-57505	20020125

RIORITY APPLN. INFO.: US 1996-594575 A2 19960131
US 1997-792553 A1 19970131
US 1999-396003 B2 19990913
EFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I US 5981200 A ***19991109***

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
I US 5981200	A	19991109	US 1997-792553	19970131 <--
PT 877805	T	20021031	PT 1997-905667	19970131
ES 2177939	T3	20021216	ES 1997-905667	19970131
US 2003186229	A1	20031002	US 2001-865291	20010524
US 2002164674	A1	20021107	US 2002-57505	20020125

B This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymic assays. Mutant green fluorescent proteins (GFPs) were created by mutagenesis of the Aequorea victoria GFP. Polyhistidine tagged tandem green and blue fluorescent proteins were recombinantly constructed having an inserted peptide sequence including cleavage recognition sites for many proteases. Cleavage expts. were done with trypsin, enterokinase and ***calpain*** .

T 78990-62-2, ***Calpain***
RL: ANT (Analyte); PEP (Physical, engineering or chemical process); ANST (Analytical study); PROC (Process)
(fluorescent fusion protein cleavage with; tandem fluorescent protein constructs and their prepn. for enzyme assays)

T 139691-88-6, Assemblin
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(of ***cytomegalovirus*** ; tandem fluorescent protein constructs and their prepn. for enzyme assays)

6 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2004 ACS on STN
CCESSION NUMBER: 1998:728567 CAPLUS
OCUMENT NUMBER: 130:10614
ITLE: Ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections
NVENTOR(S): Borgford, Thor
ATENT ASSIGNEE(S): De Novo Enzyme Corp., Can.

CODEN: PIXXD2
OCUMENT TYPE: Patent
ANGUAGE: English
AMILY ACC. NUM. COUNT: 1
ATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849311	A2	19981105	WO 1998-CA394	19980430 <--
WO 9849311	A3	19990211		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9870237	A1	19981124	AU 1998-70237	19980430 <--
EP 977862	A2	20000209	EP 1998-916743	19980430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001523961	T2	20011127	JP 1998-546437	19980430
US 6593132	B1	20030715	US 1999-403752	19991029
US 2004009551	A1	20040115	US 2003-394511	20030324

RIORITY APPLN. INFO.:
US 1997-45148P P 19970430
US 1997-63715P P 19971029
WO 1998-CA394 W 19980430
US 1999-403752 A3 19991029

I WO 9849311 A2 ***19981105***

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
I WO 9849311	A2	19981105	WO 1998-CA394	19980430 <--
WO 9849311	A3	19990211		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9870237	A1	19981124	AU 1998-70237	19980430 <--
EP 977862	A2	20000209	EP 1998-916743	19980430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001523961	T2	20011127	JP 1998-546437	19980430
US 6593132	B1	20030715	US 1999-403752	19991029
US 2004009551	A1	20040115	US 2003-394511	20030324

T Plasmid vectors
(pAP260, transfer vector for ***calpain*** -cleavable preproricin gene; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

T Plasmid vectors
(pAP262, transfer vector for ***calpain*** -cleavable preproricin gene; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

T Plasmid vectors
(pAP294, transfer vector for ***calpain*** -cleavable preproricin gene; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

T 152870-66-1 215649-49-3 215649-50-6 215649-51-7
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(***calpain*** -labile linker for ricin precursor; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

T 215649-39-1 215649-40-4
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(***cytomegalovirus*** proteinase-labile linker for ricin precursor; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

T 215649-52-8
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 215649-41-5 215649-42-6
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(***herpes*** ***simplex*** virus proteinase-labile linker for ricin precursor; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 215805-06-4 215805-20-2 215861-07-7 215861-33-9
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence, ***calpain*** cleavage of preproricin in relation to; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 215804-74-3 215804-75-4 215804-99-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence, encoding ***calpain*** cleavage site; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 215802-07-6 215802-08-7
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(nucleotide sequence, encoding cleavage site for proteinase of human ***cytomegalovirus*** ; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 215802-52-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence, ***herpes*** ***simplex*** virus proteinase cleavage of preproricin in relation to; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 215802-67-8 215802-76-9
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence, human ***cytomegalovirus*** proteinase cleavage of preproricin in relation to; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

IT 9001-01-8, Kallikrein 9004-06-2, Elastase 9025-26-7, Cathepsin D 9039-53-6, Urokinase 9047-22-7, Cathepsin B 60616-82-2, Cathepsin L 69458-91-9, Candidapepsin 78990-62-2, ***Calpain*** 79955-99-0, Matrix metalloproteinase 3 139691-88-6 141256-52-2, Matrix metalloproteinase 7 141907-41-7, Matrix metalloproteinase 146480-36-6, Matrix metalloproteinase 9
RL: CAT (Catalyst use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ricin precursors cleavable by; ricin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections)

L6 ANSWER 4 OF 26 USPATFULL on STN

ACCESSION NUMBER:	2003:296940 USPATFULL
TITLE:	Lactacystin analogs
INVENTOR(S):	Schreiber, Stuart L., Boston, MA, United States Standaert, Robert F., Bryan, TX, United States Fenteany, Gabriel, Cambridge, MA, United States Jamison, Timothy F., Cambridge, MA, United States
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6645999	B1	20031111	
	WO 9632105		19961017	<--
APPLICATION INFO.:	US 1997-945092		19970126	(8)
	WO 1996-US5072		19960412	
			19980126	PCT 371 date

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-421583, filed on 12 Apr 1995
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Travers, Russell
LEGAL REPRESENTATIVE:	Hale and Dorr LLP
NUMBER OF CLAIMS:	8

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 6645999 B1 20031111
WO 9632105 19961017 <--
SUMM The compounds disclosed herein are highly selective for the proteasome, and do not inhibit other proteases such as trypsin, .alpha.-chymotrypsin, ***calpain*** I, ***calpain*** II, papain, and cathepsin B.
SUMM . . . the X/MB1 subunit and .alpha.-chain of the proteasome and do not inhibit the activity of proteases such as trypsin, .alpha.-chymotrypsin, ***calpain*** I, ***calpain*** II, cathepsin, and papain. Such selectivity is useful to formulate a pharmaceutical composition with fewer side effects and to evaluate. .
.
SUMM Other eukaryotic transcription factors that require proteolytic processing include the general transcription factor TFIIA, ***herpes*** ***simplex*** virus VP16 accessory protein (host cell factor), virus-inducible IFN regulatory factor 2 protein, and the membrane-bound sterol regulatory element-binding protein. . .
DETD . . . .mu.M Suc-LLVY-AMC for fluorescence assay); Trypsin: 10 mM Tris-HCL, pH 8, 20 mM CaCl.sub.2 (plus 100 .mu.M Cbz-GGR-.beta.NA for assay); ***Calpain*** I: 20 mM Tris-HCL, pH 8, 1 mM CaCl.sub.2, 1 mM DTT (plus 100 .mu.M Suc-LLVY-AMC for assay); ***Calpain*** II: 20 mM Tris-HCL, pH 8, 10 mM CaCl.sub.2, 1 mM DTT (plus 100 .mu.M Suc-LLVY-AMC for assay); Papain: 50. . .
DETD
TABLE 4

Inhibition of Other Proteases
Effect of lactacystin
Protease tested (100 .mu.M)

.alpha.-Chymotrypsin No inhibition
Trypsin No inhibition
Calpain I No inhibition
Calpain II No inhibition
Papain No inhibition
Cathepsin B No inhibition
DETD . . . containing the human p105 cDNA. Forty-eight hrs after transfection, cells were pretreated for 1 hour with 0.5% DMSO, 50 .mu.M ***calpain*** inhibitor II, 50 .mu.M MG132, or 10 .mu.M .beta.-lactone. Cells were then pulse labelled with 250 uCi/plate of .sup.35S-methionine/cysteine for. . .
DETD . . . apparent, as was expected (Fan and Maniatis, 1991, Nature 354:395; Palombella et al., 1994, Cell 78:773). Pretreatment of cells with ***calpain*** inhibitor II has no effect on the processing of p105 to p50 (lane 4). However, treatment of cells with the. . .

L6 ANSWER 5 OF 26 USPATFULL on STN
ACCESSION NUMBER: 2003:190684 USPATFULL
TITLE: Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
INVENTOR(S): Borgford, Thor, Burnaby, CANADA
PATENT ASSIGNEE(S): Twinstrand Therapeutics Inc., Vancouver, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6593132	B1	20030715	
	WO 9849311		19981105	<--
APPLICATION INFO.:	US 1999-403752		19991029	(9)
	WO 1998-CA394		19980430	

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Bereskin & Parr, Gravelle, Micheline
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 254 Drawing Figure(s); 254 Drawing Page(s)
LINE COUNT: 5176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 6593132 B1 20030715
WO 9849311 19981105 <--
SUMM . . . (Proc. Natl. Acad. Sci. USA 88:107973-10800 (1991)) has described a series of viral proteases which are specifically associated

virus, varicella zoster virus-I. and infectious laryngotracheitis virus. These proteases possess similar substrate specificity and play an. . .

SUMM . . . breast cancer, prostate cancer, non small cell lung cancer, malaria, and diverse viral disease states associated with infection with human ***cytomegalovirus*** , hepatitis virus, herpes virus, human rhinovirus, infectious laryngotracheitis virus, poliomyelitis virus, or varicella zoster virus.

SUMM . . . SLSALLSSDIFN cleaved by human prostate-specific antigen; SLPRFKIIGGFN cleaved by kallikrein (bK3): SLLGIAVPGNFN cleaved by neutrophil elastase; and FFKNIVTPRTPP cleaved by ***calpain*** (calcium activated neutral protease). The nucleic acid sequences for ricin A and B chains with each of the linker sequences. . .

SUMM . . . serine, asparagine or valine. In particular embodiments, the linker amino acid sequence comprises SGVVNASCRLAN or SSYVKASVSPEN cleaved by a human ***cytomegalovirus*** protease; SALVNASSAHVN or STYLQASEKFKN cleaved by a ***herpes*** ***simplex*** 1 virus protease; SSILNASVPNFN cleaved by a human herpes virus 6 protease; SQDVNAVEASSN or SVYLQASTGYGN cleaved by a varicella zoster. . .

SUMM . . . In a particular embodiment, the cancer is T-cell or B-cell lymphoproliferative disease. In another particular embodiment, the virus is human ***cytomegalovirus*** , Epstein-Barr virus, hepatitis virus, herpes virus, human rhinovirus, infectious laryngotracheitis virus, poliomyelitis virus, or varicella zoster virus. In a further. . .

SUMM . . . cell carcinoma, gastrointestinal cancer, breast cancer, prostate cancer, non small cell lung cancer. In another embodiment, the virus is human ***cytomegalovirus*** , Epstein-Barr virus, hepatitis virus, herpes virus, human rhinovirus, human T-cell leukemia virus, infectious laryngotracheitis virus, poliomyelitis virus, or varicella zoster. . .

DRWD FIG. 47B shows the nucleotide sequence of the ***calpain*** linker region of pAP-296;

DRWD FIG. 47D shows the amino acid sequence comparison of mutant preproricin linker region of ***calpain*** to wild type;

DRWD FIG. 64 is a blot showing cleavage of pAP-296 with ***calpain*** .

DETD The nucleotide sequence of the ***calpain*** linker region of pAP-296 is referred to herein as SEQ ID NO. 124.

DETD The amino acid sequence of the mutant preproricin linker region for ***calpain*** , pAP-296, is referred to herein as SEQ ID NO. 126.

DETD In a further embodiment, the preparation of proteases from human ***cytomegalovirus*** , human herpes virus, varicalla zoster virus and infectious laryngotracheitis virus have been taught by Liu F. & Roizman, B. (J.. . .

DETD . . . for directing expression in mammalian cells generally include a promoter (e.g., derived from viral material such as polyoma, Adenovirus 2, ***cytomegalovirus*** and Simian Virus 40), as well as other transcriptional and translational control sequences. Examples of mammalian expression vectors include pCDM8. . .

DETD Cleavage of pAP-248 Protein with the Human ***Cytomegalovirus*** (HCMV) Protease

DETD Cleavage of pAP-296 Protein with ***Calpain***

DETD . . . disease-specific proteases to confirm specific cleavage in the linker region. The pAP-296 protein sample (2.05 ug) was digested with the ***Calpain*** protease (10 ug) overnight at 37.degree. C. The total volume of the digestion reaction was 35 ul and 0.761 ug of the reaction sample was loaded on a protein gel. The ***Calpain*** protease was purchased from Sigma Chemical Co., USA

DETD . . . 58 & 66(MMP-2), 60, 64 and 62 show the cleavage of proteases of linkers by HCMV, HAV 3C, MMP-2, t-PA, ***calpain*** , and human neutraphil elastase respectively. Without protease digestion, the proricin variants appear as a single band at approximately 60 kDA. . .

DETD . . . HCMV; pAP-256 by HAV3C protease; pAP-270 by MMP-2 protease; pAP-288 by t-PA protease; pAP-294 by human neutrophil elastase; pAP-296 by ***calpain*** ; and pAP-222 by MMP-2 is illustrated in FIGS. 52, 55, 59, 61, 63, 65, and 67 respectively. The appearance of. . .

DETD . . . Val Pro Gly Asn Phe Asn
1 5 10

<210> SEQ ID NO 124
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: ***Calpain*** linker region of pAP-296

<400> SEQUENCE: 124

ttttttcaaaa atattgttac tcctagaacc ccccca 36

<210> SEQ ID NO 125
<211> LENGTH: 1855
<212>. . . agcaagttat atcgaattcc tgcag 1855

<210> SEQ ID NO 126
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Mutant preproricin linker region for ***calpain*** , pAP-296

<400> SEQUENCE: 126

Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro
1 5 10

. . .
CLM What is claimed is:
. . . a matrix metalloproteinase, cathepsin L, cathepsin D, urokinase-type plasminogen activator, tissue-type plasminogen activator, human prostate-specific antigen, kallikrein, neutrophil elastase, and ***calpain*** .

. . . a cleavage recognition site for a viral protease, wherein the viral protease is selected from the group consisting of: human ***cytomegalovirus*** , human herpes virus, varicella zoster virus, hepatitis A virus, hepatitis C virus, Epstein-Barr virus-specific protease, and infectious laryngotracheitis virus.

L6 ANSWER 6 OF 26 USPATFULL on STN
ACCESSION NUMBER: 2002:115819 USPATFULL
TITLE: Fibrinogen-coated particles for therapeutic use
INVENTOR(S): Yen, Richard C. K., Yorba Linda, CA, United States
PATENT ASSIGNEE(S): Hemosphere, Inc., Anaheim, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6391343	B1	20020521	
	WO 9639128		19961212	<--
APPLICATION INFO.:	US 1998-952765		19980410	(8)
	WO 1996-US9458		19960604	
			19980410	PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-554919, filed on 9 Nov 1995, now abandoned Continuation-in-part of Ser. No. US 1995-471650, filed on 6 Jun 1995, now patented, Pat. No. US 5725804 Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 Continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 6391343 B1 20020521
WO 9639128 19961212 <--
DETD ***Calpain*** Inhibitor I
DETD ***Calpain*** Inhibitor II
DETD ***Calpain*** Inhibitor Peptide
DETD . . . double stranded), cloning vectors, coliphage DNA, lambda phage DNA, M13 DNA, Adenovirus DNA, phi-X 174 phage DNA, Simian virus DNA, ***cytomegalovirus*** DNA, Epstein-Barr Virus genes, ***Herpes*** ***Simplex*** genes, ribosomal RNA, human DNA and RNA; Genes coding for ribozymes; genes coding for antibiotics (e.g., ampicillin, chloramphenicol, cycloserine, gentamycin,. . .

CCESSION NUMBER: 2001:82299 USPATFULL
ITLE: Method and product for cleaning and/or whitening of teeth
NVENTOR(S): Rinne, Ari, Pajutie 3 B, FIN-2G900 Turku, Finland

	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 6241973	B1	20010605	
	WO 9829088		19980709	<--
PPLICATION INFO.:	US 1999-331777		19990624	(9)
	WO 1998-FI1		19980102	
			19990624	PCT 371 date
			19990624	PCT 102(e) date

	NUMBER	DATE
RIORITY INFORMATION:	FI 1997-12	19970103

OCUMENT TYPE: Utility
LE SEGMENT: Granted
RIMARY EXAMINER: Rose, Shep K.
EGAL REPRESENTATIVE: Lydon, James C.
UMBER OF CLAIMS: 12
XEMPLARY CLAIM: 1
INE COUNT: 583
AS INDEXING IS AVAILABLE FOR THIS PATENT.
US 6241973 B1 20010605
WO 9829088 19980709 <--

MM Among the mammalian cysteine proteinases are further known calcium-activated cysteine proteinases, which are considered to belong to the ***calpain*** family. Their inhibitors are called calpastatins (M. Nakamura, s. Imajoh-Ohmi, K, Suzuki and S. Kawashima: An endogenous inhibitor of calcium-activated. . .

MM . . . 3. Installment 1995; Bjorck, L., Grubb, A. and Kjellen, L. (1990) Cystatin C, a human proteinase inhibitor, blocks replication of ***Herpes*** ***simplex*** virus. J Virol 64, 941-943Bjorck, L., Akesson, P., Bohus, M., Trojnar, J., Abrahamson, M., Olafson, I., and Grubb, A. (1989). . .

MM . . . protein chemistry as well as produced by molecular biological techniques. Most of such cysteine proteinases belong to the cathepsin or ***calpain*** family.

ANSWER 8 OF 26 USPATFULL on STN
CCESSION NUMBER: 2000:41033 USPATFULL
ITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
VENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Doctrow, Susan Robin, Roslindale, MA, United States
TENT ASSIGNEE(S): Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
TENT INFORMATION:	US 6046188		20000404	
	WO 9640148		19961219	<--
PLICATION INFO.:	US 1998-973577		19980311	(8)
	WO 1996-US10037		19960606	
			19980311	PCT 371 date
			19980311	PCT 102(e) date

LATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-485489, filed on 7 Jun 1995, now patented, Pat. No. US 5696109
CUMENT TYPE: Utility
LE SEGMENT: Granted
IMARY EXAMINER: Reamer, James H.
GAL REPRESENTATIVE: Townsend & Townsend & Crew LLP
MBER OF CLAIMS: 24
EMPLARY CLAIM: 1
MBER OF DRAWINGS: 28 Drawing Figure(s); 16 Drawing Page(s)
NE COUNT: 3405
S INDEXING IS AVAILABLE FOR THIS PATENT.
US 6046188 20000404
WO 9640148 19961219 <--

MM . . . effects in treating systemic lupus erythematosus, Crohn's disease, gastric ulcers, oxygen toxicity, burned patients, renal failure attendant to transplantation, and ***herpes*** ***simplex*** infection.

MM . . . (3) one or more oxyradical inhibitors, such as desferrioxamine

calpain inhibitors. The formulations of these compositions is dependent upon the specific pathological condition sought to be treated or prevented, the. . .

D . . . active ingredients, typically selected from the group consisting of: N-2-mercaptopropionylglycine, N-acetylcysteine, glutathione, dimethyl thiourea, desferrioxamine, mannitol, .alpha.-tocopherol, ascorbate, allopurinol, 21-aminosteroids, ***calpain*** inhibitors, glutamate receptor antagonists, tissue plasminogen activator, streptokinase, urokinase, nonsteroidal anti-inflammatory agent, cortisone, and carotenoids. Antioxidant salen-Mn complexes may also. . .

ANSWER 9 OF 26 USPATFULL on STN

ESSION NUMBER:	1999:166974 USPATFULL
LE:	Cysteine protease inhibitors
ENTOR(S):	Spruce, Lyle W., Chula Vista, CA, United States Gyorkos, Albert C., Westminster, CO, United States Cheronis, John C., Conifer, CO, United States Goodfellow, Val S., Tucson, AZ, United States Leimer, Axel H., Westborough, MA, United States Young, John M., Redwood City, CA, United States Gerrity, James Ivan, Albany, OR, United States
ENT ASSIGNEE(S):	Cortech Inc., Bedminster, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
ENT INFORMATION:	US 6004933		19991221	<--
LICATION INFO.:	US 1998-65258		19980423	(9)

	NUMBER	DATE
ORITY INFORMATION:	US 1997-44819P	19970425 (60)

UMENT TYPE:	Utility
E SEGMENT:	Granted
MARY EXAMINER:	Richter, Johann
ISTANT EXAMINER:	Solola, Taofiq A.
AL REPRESENTATIVE:	Dechert Price & Rhoads
BER OF CLAIMS:	146
MPLARY CLAIM:	1
BER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)
E COUNT:	2591

INDEXING IS AVAILABLE FOR THIS PATENT.

US 6004933 19991221 <--

M . . . comprise a family of intracellular cysteine proteases which are ubiquitously expressed in mammalian tissues. Three major calpains have been identified: ***calpain*** I and II, and p94. The ***calpain*** family of cysteine proteases has been implicated in many diseases and disorders, including stroke, neurodegeneration, such as Alzheimer's disease, amyotrophy and motor neuron damage; acute central nervous system injury, muscular dystrophy, bone resorption, platelet aggregation, cataracts and inflammation. ***Calpain*** I has been implicated in excitatory amino-acid induced neurotoxicity disorders including ischemia, hypoglycemia and epilepsy. The cysteine protease p94, a muscle-specific member of the ***calpain*** family, has been identified as a gene product responsible for limb girdle muscular dystrophy (Barrett A. J., et al. ICOP. . .

M Where Z is a ***calpain*** binding moiety, preferably R.sub.2 is benzyl optionally substituted with alkoxy; H.sub.2 NC(=.sup.+ NH.sub.2)NHCH.sub.2 CH.sub.2 CH.sub.2 --; --R'--C(=.sup.30 NH.sub.2)NH.sub.2 ; --R'--NHC(=.sup.+. . .

D TABLE 1

teine proteases and exemplary recognition elements.

teine tease	P1	P2	Other	Reference
Calpain	I and II			
large hydrophobic		Leu, bulky		18
e.g. Nva, Phe, Abu		aliphatic, hPhe		
Calpain	I			
Arg or Arg-mimetic, Lys, Tyr,		t-butyl-Gly, Leu,		38

Val, Nle, Tyr(O-
Bzl), Leu, Abu, Phe
ain hPhe,. . .
D . . . .alpha., .beta. and .gamma.) (rice), bromelain (including
stem-and fruit bromelain), ficin, thaumatopain (Thaumatococcus);
gingipain R and gingipain K; calpains, including ***calpain***
(Schistosoma), ***calpain*** I, ***calpain*** II,
calpain p94, calcium-binding protein PMP41, sol gene product
(Drosophila); streptopain and cysteine endopeptidase (Porphyromonas);
picomain 2A, picornain 3C, apothovirus endopeptidase, cardiovirus. . .
D . . . associated syndromes--septic shock (including Gram-negative
sepsis), HIVinfection and AIDS, genital herpes, zoster, chickenpox, EBV
infections and encephalitis, CMV-choreoretinitis or encephalitis,
cytomegalovirus infections in neonates (including related
pneumonitis), opportunistic infections in immunocompromised individuals
(including AIDS and transplant patients), dysentery, hepatitis C,
hepatitis. . .
D . . . colon, kidney; osteo-,
(1990); Gordon, Seminars in
chondro-, and liposarcoma;
Thrombosis and Hemostasis,
neuroblastoma; melanoma;
18:424-433 (1992)
nonlympocytic leukemia;
lymphocytic leukemia)
Calpain I and II
Osteoporosis, stroke, CNS
Karlsson, et al., Neurobiology
injury, Alzheimer's disease
of Aging, 16:901-906 (1995);
Additionally, diseases involving
Squier, et al., J. Cell.
dysregulated apoptosis as listed
Physiol., 159:229-237
for caspase above.
(1994).
Calpain p94 Muscular dystrophy
Calpain p94 and limb-girdle
muscular dystrophy, ICOP
Letters 1996.
atitis C Virus
Hepatitis C Grakoui, et al., Proc. Nat.
opeptidase 2 and Acad.. . .
What is claimed is:
15. An inhibitor of claim 10 wherein Z is a ***calpain*** binding
moiety.

109. A method of inhibiting the enzymatic activity of a ***calpain***
cysteine protease comprising contacting a protease with an inhibitory
amount of a compound of claim 15.

ANSWER 10 OF 26 USPATFULL on STN
ESSION NUMBER: 1999:155518 USPATFULL
LE: Viral production process
ENTOR(S): Giroux, Daniel D., La Jolla, CA, United States
Goudreau, Ann M., San Diego, CA, United States
Ramachandra, Muralidhara, San Diego, CA, United States
Shabram, Paul W., Olivenhain, CA, United States
ENT ASSIGNEE(S): Canji, Inc., San Diego, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE	
ENT INFORMATION:	US 5994134		19991130	<--
LICATION INFO.:	US 1998-73076		19980504 (9)	
UMENT TYPE:	Utility			
E SEGMENT:	Granted			
MARY EXAMINER:	Stucker, Jeffrey			
AL REPRESENTATIVE:	Murphy, Richard B.			
BER OF CLAIMS:	17			
MPLARY CLAIM:	1			
BER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)			
E COUNT:	1005			

INDEXING IS AVAILABLE FOR THIS PATENT.
US 5994134 19991130 <--

vectors containing a DNA sequence encoding p53 under control of the ***cytomegalovirus*** promoter region and the tripartite leader sequence having E3 under control of the CMV promoter and deletion of E4 coding. . .

ETD . . . to the serum free media which down-regulate or inhibit the transgene promoter. For example, when the transgene promoter is the ***cytomegalovirus*** early promoter (CMV), elements such as neuramidase or tunicamycin may be added to suppress the CMV promoter during the culture.

ETD . . . transgene expression but should not materially interfere with the expression of viral genes essential to viral replication. For example, the ***cytomegalovirus*** major immediate early promoter is a promoter commonly used to constitutively drive transgene expression. This promoter contains binding sites for. . .

ETD . . . invention provides a method to increase the infectivity of producer cell lines for viral infectivity by the inclusion of a ***calpain*** inhibitor. Examples of ***calpain*** inhibitors useful in the practice of the present invention include ***calpain*** inhibitor 1 (also known as N-acetyl-leucyl-leucyl-norleucinal, commercially available from Boehringer Mannheim). ***Calpain*** inhibitor 1 was observed to increase the infectivity of producer cell lines to recombinant adenovirus.

6 ANSWER 11 OF 26 USPATFULL on STN

CCESSION NUMBER:	1999:137014 USPATFULL			
ITLE:	Vesicle transport related protein			
NVENTOR(S):	Lal, Preeti, Santa Clara, CA, United States Corley, Neil C., Mountain View, CA, United States Shah, Purvi, Sunnyvale, CA, United States			
ATENT ASSIGNEE(S):	Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 5976865		19991102	<--
PPLICATION INFO.:	US 1997-984172		19971203	(8)
OCUMENT TYPE:	Utility			
ILE SEGMENT:	Granted			
RIMARY EXAMINER:	Johnson, Nancy A.			
EGAL REPRESENTATIVE:	Incyte Pharmaceuticals, Inc.			
UMBER OF CLAIMS:	10			
XEMPLARY CLAIM:	1			
UMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)			
INE COUNT:	2242			

AS INDEXING IS AVAILABLE FOR THIS PATENT.

I US 5976865 19991102 <--

ETD . . . number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the ***herpes*** ***simplex*** virus thymidine kinase genes (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase genes (Lowy, I. et al. (1980). . .

ETD . . . a modifier of the spectrin-binding activity of ankyrin. In particular, cleavage of the ANK1 region from mouse erythrocyte ankyrin by ***calpain*** reduces spectrin-binding activity of the remaining 195 kDa fragment.about.8-fold (Hall, T. G. and V. Bennett (1987) J. Biol. Chem. 262:10537-45). VTRP activity is therefore measured by comparing the spectrin-binding activity of the 195 kDa ***calpain*** fragment with a chimeric recombinant protein containing VTRP integrated with the 195 kDa ***calpain*** fragment. Spectrin binding is measured by incubating the VTRP recombinant protein or 195 kDa fragment with radiolabeled-.sup.14 C-spectrin together in. . .

6 ANSWER 12 OF 26 USPATFULL on STN

CCESSION NUMBER:	1999:102423 USPATFULL			
ITLE:	Method for making non-crosslinked protein particles for therapeutic and diagnostic use			
NVENTOR(S):	Yen, Richard C. K., Glendora, CA, United States			
ATENT ASSIGNEE(S):	Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 5945033		19990831	<--
PPLICATION INFO.:	US 1996-747137		19961112	(8)
ELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 which is a			

on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
OCUMENT TYPE: Utility
ILE SEGMENT: Granted
RIMARY EXAMINER: Dees, Jose' G.
SSISTANT EXAMINER: Hartley, Michael G.
EGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
UMBER OF CLAIMS: 12
XEMPLARY CLAIM: 1
INE COUNT: 3655
AS INDEXING IS AVAILABLE FOR THIS PATENT.
I US 5945033 19990831 <--
ETD ***Calpain*** Inhibitor I
ETD ***Calpain*** Inhibitor II
ETD ***Calpain*** Inhibitor Peptide
ETD . . . double stranded), cloning vectors, coliphage DNA, lambda phage DNA, M13 DNA, Adenovirus DNA, phi-X 174 phage DNA, Simian virus DNA, ***cytomegalovirus*** DNA, Epstein-Barr Virus genes, ***Herpes*** ***Simplex*** genes, ribosomal RNA, human DNA and RNA; Genes coding for ribozymes; genes coding for antibiotics (e.g., ampicillin, chloramphenicol, cycloserine, gentamycin,. . .

6 ANSWER 13 OF 26 USPATFULL on STN
CCESSION NUMBER: 1999:81758 USPATFULL
ITLE: Non-activated receptor complex proteins and uses thereof
NVENTOR(S): Davis, Roger J., Princeton, MA, United States
Galcheva-Gargova, Zoya, Worcester, MA, United States
ATENT ASSIGNEE(S): University of Massachusetts, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 5925566		19990720	<--
PPLICATION INFO.:	US 1997-870518		19970606	(8)

	NUMBER	DATE
RIORITY INFORMATION:	US 1996-19219P	19960606 (60)

OCUMENT TYPE: Utility
ILE SEGMENT: Granted
RIMARY EXAMINER: Campell, Bruce R.
SSISTANT EXAMINER: Nguyen, Dave Trong
EGAL REPRESENTATIVE: Fish & Richardson, P.C.
UMBER OF CLAIMS: 23
XEMPLARY CLAIM: 1
UMBER OF DRAWINGS: 22 Drawing Figure(s); 18 Drawing Page(s)
INE COUNT: 2438
AS INDEXING IS AVAILABLE FOR THIS PATENT.
I US 5925566 19990720 <--
ETD . . . interaction. In initial experiments, we examined the effect of proteolytic cleavage of the COOH terminus of the EGF receptor with ***calpain*** as follows. ***Calpain*** cleavage of the EGF receptors was performed by harvesting cells in lysis buffer without EDTA, PMSF, leupeptin, and aprotinin [Gregoriou. . . at 4.degree. C., and standard binding assays were performed as described herein. We found that both the wild-type and the ***calpain*** -cleaved EGF receptor bound to the ZPR1 zinc fingers.
ETD Since the major sites of ***calpain*** -cleavage of the EGF receptor are Gln.sup.996 and Asp.sup.1059 [Gregoriou et al., Eur. J. Biochem. 223, 455 (1994)], we concluded that. . .
ETD For gene therapy, ZPR1 cDNA expression is directed from any suitable promoter (e.g., the human ***cytomegalovirus*** , simian virus 40, or metallothionein promoters), and its production is regulated by any desired mammalian regulatory element. For example, if. . .

6 ANSWER 14 OF 26 USPATFULL on STN
CCESSION NUMBER: 1999:36949 USPATFULL
ITLE: Engineering oral tissues
NVENTOR(S): Mooney, David J., Ann Arbor, MI, United States
Rutherford, Robert B., Ann Arbor, MI, United States
ATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

ATENT INFORMATION:	US 5885829	19990323	<--
PPLICATION INFO.:	US 1997-864494	19970528 (8)	

	NUMBER	DATE
RIORITY INFORMATION:	US 1996-18450P	19960528 (60)

OCUMENT TYPE: Utility
LE SEGMENT: Granted
RIMARY EXAMINER: Degen, Nancy
EGAL REPRESENTATIVE: Arnold, White & Durkee
UMBER OF CLAIMS: 109
XEMPLARY CLAIM: 1
UMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)
INE COUNT: 8001
AS INDEXING IS AVAILABLE FOR THIS PATENT.

US 5885829 19990323 <--

LTD . . . shown to prevent apoptosis and cell cycle effects induced by camptothecin and topotecan in HL-60 cells (Traganos et al., 1993). ***Calpain*** inhibitor I inhibits apoptosis in thymocytes and metamyelocytes (Squier et al., 1994), while leupeptin, ***calpain*** inhibitor II and the E64 class of serine protease inhibitors have also been shown to inhibit activation-induced programmed cell death. . .

LTD . . . cleavage in thymocytes without the involvement of endonucleases (Cain et al., 1994). The cysteine protease inhibitors E64 and leupeptin, the ***calpain*** selective inhibitor acetyl-leucyl-leucyl-normethional, and the serine protease inhibitors diisopropylfluorophosphate and phenylmethylsulfonyl fluoride were all shown to selectively block T-cell receptor-triggered. . .

TD In various other embodiments, the human ***cytomegalovirus*** (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used. . .

TD . . . 1988; Rowen et al., 1988; Berkhout et al., 1989; Laspia et al., 1989; Sharp and Marciniak, 1989; Braddock et al., 1989

Cytomegalovirus Weber et al., 1984; Boshart et al., 1985; Foecking and Hofstetter, 1986

bbon Ape Leukemia Virus
Holbrook et al., 1987; Quinn. . .

TD . . . Weber, Jahn, Dorsch-Hasler, Fleckenstein, and Schaffner, "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human ***Cytomegalovirus*** ," Cell, 41:521, 1985.

TD Squier, M. K., Miller, A. C., Malkinson, A. M. and Cohen, J. J., " ***Calpain*** activation in apoptosis," J. Cell. Physiol. 159:229-237, 1994.

ANSWER 15 OF 26 USPATFULL on STN

CESSION NUMBER:	1998:138941 USPATFULL
TLE:	Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
VENTOR(S):	Malfroy-Camine, Bernard, Arlington, MA, United States Doctrow, Susan Robin, Roslindale, MA, United States
TENT ASSIGNEE(S):	Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
TENT INFORMATION:	US 5834509		19981110	<--
PLICATION INFO.:	US 1995-479697		19950607 (8)	
LATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-380731, filed on 26 Jan 1995 which is a continuation-in-part of Ser. No. US 1992-987474, filed on 7 Dec 1992, now patented, Pat. No. US 5403834			

	NUMBER	DATE
IORITY INFORMATION:	WO 1993-US11857	19931206

CUMENT TYPE: Utility
LE SEGMENT: Granted
IMARY EXAMINER: Jarvis, William R. A.
GAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
MBER OF CLAIMS: 5
EMPLARY CLAIM: 1
MBER OF DRAWINGS: 28 Drawing Figure(s); 19 Drawing Page(s)
NE COUNT: 3384

I US 5834509 19981110 <--
UMM . . . effects in treating systemic lupus erythematosus, Crohn's disease, gastric ulcers, oxygen toxicity, burned patients, renal failure attendant to transplantation, and ***herpes*** ***simplex*** infection.
UMM . . . (3) one or more oxyradical inhibitors, such as desferrioxamine or allopurinol, and/or one or more biological modifier agents, such as ***calpain*** inhibitors. The formulations of these compositions is dependent upon the specific pathological condition sought to be treated or prevented, the. . .
ETD . . . active ingredients, typically selected from the group consisting of: N-2-mercaptopropionylglycine, N-acetylcysteine, glutathione, dimethyl thiourea, desferrioxamine, mannitol, .alpha.-tocopherol, ascorbate, allopurinol, 21-aminosteroids, ***calpain*** inhibitors, glutamate receptor antagonists, tissue plasminogen activator, streptokinase, urokinase, nonsteroidal anti-inflammatory agent, cortisone, and carotenoids. Antioxidant salen-Mn complexes may also. . .

6 ANSWER 16 OF 26 USPATFULL on STN
CCESSION NUMBER: 1998:134999 USPATFULL
ITLE: Methods for the treatment of bone resorption disorders, including osteoporosis
NVENTOR(S): Gelb, Bruce D., Dobbs Ferry, NY, United States
Chapman, Harold, Newton, MA, United States
Desnick, Robert J., New York, NY, United States
ATENT ASSIGNEE(S): Mount Sinai School of Medicine of the City of New York, New York, NY, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 5830850		19981103	<--
PPLICATION INFO.:	US 1996-704473		19960828	(8)

OCUMENT TYPE: Utility
ILE SEGMENT: Granted
RIMARY EXAMINER: Marschel, Ardin H.
EGAL REPRESENTATIVE: Pennie & Edmonds LLP
UMBER OF CLAIMS: 5
XEMPLARY CLAIM: 1
UMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
INE COUNT: 2434
AS INDEXING IS AVAILABLE FOR THIS PATENT.
I US 5830850 19981103 <--
ETD . . . Science 244:1288-1292; Capecchi, 1989, Trends in Genet. 5:70-76). Utilizing the PNS method, nonhomologous recombinants are selected against by using the ***Herpes*** ***Simplex*** virus thymidine kinase (HSV-TK) gene and selecting against its nonhomologous insertion with herpes drugs such as gancyclovir or FIAU. By. . .
ETD . . . is notable that another genetic disorder (limb-girdle muscular dystrophy Type 2A) caused by the deficiency of a neutral cysteine protease, ***calpain*** 3, was recently identified in which presumably related families on a small island had different mutations (Richard, I et al., 1995, Cell 81:27-40). ***Calpain*** 3 belongs to a family of calpains, analogous to the cathepsin family. The finding of multiple mutations in ***Calpain*** 3 suggested to Richard et al. that a "digenic" model in which only in the presence of specific alleles at a permissive second locus (e.g., a compensatory, partially redundant, regulatory, or modifier gene) will there be expression of ***calpain*** mutations. Since one would need mutations at both loci to be affected, the disease prevalence would remain low. By analogy,. . .

6 ANSWER 17 OF 26 USPATFULL on STN
CCESSION NUMBER: 1998:131743 USPATFULL
ITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
NVENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Doctrow, Susan Robin, Roslindale, MA, United States
ATENT ASSIGNEE(S): Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 5827880		19981027	<--

LATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-987474, filed on 7 Dec 1992, now patented, Pat. No. US 5403834
CUMENT TYPE: Utility
LE SEGMENT: Granted
IMARY EXAMINER: Nazario-Gonzalez, Porfirio
GAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
MBER OF CLAIMS: 13
EMPLARY CLAIM: 1,12
MBER OF DRAWINGS: 28 Drawing Figure(s); 19 Drawing Page(s)
NE COUNT: 3241
S INDEXING IS AVAILABLE FOR THIS PATENT.
US 5827880 19981027 <--
MM . . . effects in treating systemic lupus erythematosus, Crohn's disease, gastric ulcers, oxygen toxicity, burned patients, renal failure attendant to transplantation, and ***herpes*** ***simplex*** infection.
MM . . . (3) one or more oxyradical inhibitors, such as desferrioxamine or allopurinol, and/or one or more biological modifier agents, such as ***calpain*** inhibitors. The formulations of these compositions is dependent upon the specific pathological condition sought to be treated or prevented, the. . .
TD . . . active ingredients, typically selected from the group consisting of: N-2-mercaptopropionylglycine, N-acetylcysteine, glutathione, dimethyl thiourea, desferrioxamine, mannitol, .alpha.-tocopherol, ascorbate, allopurinol, 21-aminosteroids, ***calpain*** inhibitors, glutamate receptor antagonists, tissue plasminogen activator, streptokinase, urokinase, nonsteroidal anti-inflammatory agent, cortisone, and carotenoids. Antioxidant salen-Mn complexes may also. . .

ANSWER 18 OF 26 USPATFULL on STN
CESSION NUMBER: 1998:58182 USPATFULL
TLE: Lactacystin analogs
VENTOR(S): Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
TENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
TENT INFORMATION:	US 5756764		19980526	<--
PLICATION INFO.:	US 1995-466468		19950606 (8)	

LATED APPLN. INFO.: Division of Ser. No. US 1995-421583, filed on 12 Apr 1995
CUMENT TYPE: Utility
LE SEGMENT: Granted
IMARY EXAMINER: Richter, Johann
SISTANT EXAMINER: Stockton, Laura L.
GAL REPRESENTATIVE: Fish & Richardson P.C.
MBER OF CLAIMS: 16
EMPLARY CLAIM: 1
NE COUNT: 2392
S INDEXING IS AVAILABLE FOR THIS PATENT.
US 5756764 19980526 <--
MM The compounds disclosed herein are highly selective for the proteasome, and do not inhibit other proteases such as trypsin, .alpha.-chymotrypsin, ***calpain*** I, ***calpain*** II, papain, and cathepsin B.
MM . . . the X/MB1 subunit and .alpha.-chain of the proteasome and do not inhibit the activity of proteases such as trypsin, .alpha.-chymotrypsin, ***calpain*** I, ***calpain*** II, cathepsin, and papain. Such selectivity is useful to formulate a pharmaceutical composition with fewer side effects and to evaluate. . .
MM Other eukaryotic transcription factors that require proteolytic processing include the general transcription factor TFIIA, ***herpes*** ***simplex*** virus VP16 accessory protein (host cell factor), virus-inducible IFN regulatory factor 2 protein, and the membrane-bound sterol regulatory element-binding protein. . .
TD . . . .mu.M Suc-LLVY-AMC for fluorescence assay); Trypsin: 10 mM Tris-HCL, pH 8, 20 mM CaCl.sub.2 (plus 100 .mu.M Cbz-GGR-.beta.NA for assay); ***Calpain*** I: 20 mM Tris-HCL, pH 8, 1 mM CaCl.sub.2, 1 mM DTT (plus 100 .mu.M Suc-LLVY-AMC for assay); ***Calpain*** II: 20 mM Tris-HCL, pH 8, 10 mM CaCl.sub.2, 1 mM DTT (plus 100 .mu.M Suc-LLVY-AMC

ETD TABLE 4

nhibition of Other Proteases
Effect of lactacystin (100
rotease tested
.mu.M)

alpha.-Chymotrypsin
No inhibition
rypsin No inhibition
Calpain I No inhibition
Calpain II No inhibition
apain No inhibition
athepsin B No inhibition

ETD . . . containing the human p105 cDNA. Forty-eight hrs after transfection, cells were pretreated for 1 hour with 0.5% DMSO, 50 .mu.M ***calpain*** inhibitor II, 50 .mu.M MG132, or 10 .mu.M .beta.-lactone. Cells were then pulse labelled with 250 uCi/plate of .sup.35 S-methionine/cysteine. . .

ETD . . . apparent, as was expected (Fan and Maniatis, 1991, Nature 354:395; Palombella et al., 1994, Cell 78:773). Pretreatment of cells with ***calpain*** inhibitor II has no effect on the processing of p105 to p50 (lane 4). However, treatment of cells with the. . .

6 ANSWER 19 OF 26 USPATFULL on STN
CCESSION NUMBER: 1998:57716 USPATFULL
ITLE: Aptamers specific for biomolecules and methods of making
NVENTOR(S): Griffin, Linda, Atherton, CA, United States
Albrecht, Glenn, Redwood City, CA, United States
Latham, John, Palo Alto, CA, United States
Leung, Lawrence, Hillsborough, CA, United States
Vermaas, Eric, Oakland, CA, United States
Toole, John J., Burlingame, CA, United States
ATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
ATENT INFORMATION:	US 5756291		19980526	<--
PPLICATION INFO.:	US 1995-484192		19950607 (8)	

ELATED APPLN. INFO.: Continuation of Ser. No. US 1992-934387, filed on 21 Aug 1992, now abandoned
OCUMENT TYPE: Utility
ILE SEGMENT: Granted
RIMARY EXAMINER: Zitomer, Stephanie W.
EGAL REPRESENTATIVE: Bosse, Mark L.
UMBER OF CLAIMS: 12
XEMPLARY CLAIM: 1
UMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
INE COUNT: 8242
AS INDEXING IS AVAILABLE FOR THIS PATENT.
I US 5756291 19980526 <--
ETD . . . (HA)
euraminidase (NA)
ucleoprotein (NP)
1 and M2 proteins
S1 and NS2 proteins
epatitis B
nvelope (surface antigenP proteins (including pre-S1, re-S2 and S)
ucleocapsid (core) proteins
-gene product
-gene product
Cytomegalovirus
mmediate early (alpha) gene products (including IE1 and E2)
arly (beta) gene products (including DNA pol p140, DBP52 DBP 140)
ate (gamma) structural gene products
Herpes ***Simplex*** Virus
hymidine kinase
ibonucleotide reductase
irus-encoded envelope glycoproteins
pstein-Barr Virus

RLF1 protein)
early gene products (including SMLF1, MRF1, ALF2,. . . synthase
alanine aminotransferase
alcohol dehydrogenase
aldolase
adose reducase
alkaline phosphatase
amidophosphodbosylanine transferase
AMP phosphodiesterase
amyloid b/A4 protein
amyloid precursor protein
ankarin
arginase
argininosuccinate lyase
argininosuccinate synthetase
aromatase
aryl sulfatase
aspartate aminotransferase
aspartate transcarbamoylase
ATP diphosphohydrolase
ATPase
b-actin
b-glucuronidase
b-glycerophosphatase
b-ketoacyl-ACP reductase
b-ketoacyl-ACP sythetase
b-spectrin
b-tropomyosin
b-tubulin
C5a inactivation factor
calcitoin
calmodulin
    calpain   I
calreticulin
carbamoyl-phosphate synthetase
carbonic anhydrase
casein kinase 1
casein kinase 2
catalase
catechol methyltransferase
cathepsin
cathepsin B and L
cdc 2 p34
cdc 10
cdc 13 p60
cdc 25 p80
chaparonin
cholesterol esterase
cholesterol monooxygenase
citrate. . .

L6 ANSWER 20 OF 26 USPATFULL on STN
ACCESSION NUMBER: 1998:24868 USPATFULL
TITLE: Non-crosslinked protein particles for therapeutic and diagnostic use
INVENTOR(S): Yen, Richard C. K., Yorba Linda, CA, United States
PATENT ASSIGNEE(S): Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5725804		19980310	<--
APPLICATION INFO.:	US 1995-471650		19950606	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 which is a continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Townsend & Townsend & Crew
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5725804 19980310 <--
DETD ***Calpain*** Inhibitor I
DETD ***Calpain*** Inhibitor II
DETD ***Calpain*** Inhibitor Peptide
DETD . . . double stranded), cloning vectors, coliphage DNA, lambda phage DNA, M13 DNA, Adenovirus DNA, phi-X 174 phage DNA, Simian virus DNA, ***cytomegalovirus*** DNA, Epstein-Barr Virus genes, ***Herpes*** ***Simplex*** genes, ribosomal RNA, human DNA and RNA; Genes coding for ribozymes; genes coding for antibiotics (e.g., ampicillin, chloramphenicol, cycloserine, gentamycin,. . .

L6 ANSWER 21 OF 26 USPATFULL on STN
ACCESSION NUMBER: 97:115268 USPATFULL
TITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
INVENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Doctrow, Susan Robin, Roslindale, MA, United States
PATENT ASSIGNEE(S): Eukarion, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5696109		19971209 <--
APPLICATION INFO.:	US 1995-485489		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-380731, filed on 26 Jan 1995 which is a continuation-in-part of Ser. No. US 1992-987474, filed on 7 Dec 1992, now patented, Pat. No. US 5403834		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1993-US11857	19931206

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5696109 19971209 <--
SUMM . . . effects in treating systemic lupus erythematosus, Crohn's disease, gastric ulcers, oxygen toxicity, burned patients, renal failure attendant to transplantation, and ***herpes*** ***simplex*** infection.
SUMM . . . (3) one or more oxyradical inhibitors, such as desferrioxamine or allopurinol, and/or one or more biological modifier agents, such as ***calpain*** inhibitors. The formulations of these compositions is dependent upon the specific pathological condition sought to be treated or prevented, the. . .
DETD . . . active ingredients, typically selected from the group consisting of: N-2-mercaptopropionylglycine, N-acetylcysteine, glutathione, dimethyl thiourea, desferrioxamine, mannitol, .alpha.-tocopherol, ascorbate, allopurinol, 21-aminosteroids, ***calpain*** inhibitors, glutamate receptor antagonists, tissue plasminogen activator, streptokinase, urokinase, nonsteroidal anti-inflammatory agent, cortisone, and carotenoids. Antioxidant salen-Mn complexes may also. . .

L6 ANSWER 22 OF 26 USPATFULL on STN
ACCESSION NUMBER: 97:26904 USPATFULL
TITLE: Non-crosslinked protein particles for therapeutic and diagnostic use
INVENTOR(S): Yen, Richard C. K., Glendora, CA, United States
PATENT ASSIGNEE(S): Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616311		19970401 <--
APPLICATION INFO.:	US 1994-212546		19940314 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat.		

No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Townsend & Townsend & Crew
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1,26
LINE COUNT: 2585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5616311 19970401 <--
DETD ***Calpain*** Inhibitor I
DETD ***Calpain*** Inhibitor II
DETD ***Calpain*** Inhibitor Peptide
DETD . . . double stranded), cloning vectors, coliphage DNA, lambda phage DNA, M13 DNA, Adenovirus DNA, phi-X 174 phage DNA, Simian virus DNA, ***cytomegalovirus*** DNA, Epstein-Bart Virus genes, ***Herpes*** ***Simplex*** genes, ribosomal RNA, human DNA and RNA; Genes coding for ribozymes; genes coding for antibiotics (e.g., ampicillin, chloramphenicol, cycloserine, gentamycin,. . .

L6 ANSWER 23 OF 26 USPATFULL on STN
ACCESSION NUMBER: 95:29636 USPATFULL
TITLE: Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
INVENTOR(S): Malfroy-Camine, Bernard, Arlington, MA, United States
Baudry, Michel, Long Beach, CA, United States
PATENT ASSIGNEE(S): Eukarion, Inc., Arlington, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5403834		19950404	<--
APPLICATION INFO.:	US 1992-987474		19921207	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Henley, III, Raymond
ASSISTANT EXAMINER: Criares, T. J.
LEGAL REPRESENTATIVE: Dunn, Tracy J.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5403834 19950404 <--
SUMM . . . effects in treating systemic lupus erythematosus, Crohn's disease, gastric ulcers, oxygen toxicity, burned patients, renal failure attendant to transplantation, and ***herpes*** ***simplex*** infection.
SUMM . . . (3) one or more oxyradical inhibitors, such as desferrioxamine or allopurinol, and/or one or more biological modifier agents, such as ***calpain*** inhibitors. The formulations of these compositions is dependent upon the specific pathological condition sought to be treated or prevented, the. . .
DETD . . . active ingredients, typically selected from the group consisting of: N-2-mercaptopropionylglycine, N-acetylcysteine, glutathione, dimethyl thiourea, desferrioxamine, mannitol, .alpha.-tocopherol, ascorbate, allopurinol, 21-aminosteroids, ***calpain*** inhibitors, glutamate receptor antagonists, tissue plasminogen activator, streptokinase, urokinase, nonsteroidal anti-inflammatory agent, cortisone, and carotenoids. Antioxidant salen-Mn complexes may also. . .

L6 ANSWER 24 OF 26 USPATFULL on STN
ACCESSION NUMBER: 94:51514 USPATFULL
TITLE: Antiplatelet and antithrombotic activity of platelet glycoprotein Ib receptor fragments
INVENTOR(S): Handin, Robert, Needham, MA, United States
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5321127		19940614	<--
APPLICATION INFO.:	US 1991-670606		19910318	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

GAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox
MBER OF CLAIMS: 9
EMPLARY CLAIM: 1
MBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
NE COUNT: 1494
S INDEXING IS AVAILABLE FOR THIS PATENT.
US 5321127 19940614 <--
MM . . . et al., Blood 67:19-26 (1986)). It is cleaved from the surface of intact platelets by various maneuvers which activate platelet ***calpain*** , an endogenous calcium dependent protease (Fox, J. E., et al., J. Biol. Chem. 263:4882-4890 (1988)). Further digestion of glycocalicin with. . .
TD . . . at the Massachusetts General Hospital, Boston Mass. to produce pCDM8-GpIba. The CDM8 vector contains a cloning site downstream from the ***cytomegalovirus*** promoter as well as the SV40 origin of replication, permitting transient expression of the heterologous protein in COS cells (Aruffo,. . .

ANSWER 25 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
CESSION NUMBER: 1999:184941 BIOSIS
CUMENT NUMBER: PREV199900184941
TLE: Human ***cytomegalovirus*** -activated ***calpain*** and p21Cip1 degradation in human lung fibroblasts.
THOR(S): Chen, Z.; Knutson, E.; Kurosky, A.; Liu, S.; Albrecht, T.
RPORATE SOURCE: Univ. Texas Med. Branch, Galveston, TX 77555, USA
URCE: Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1999) Vol. 40, pp. 447-448. print. Meeting Info.: 90th Annual Meeting of the American Association for Cancer Research. Philadelphia, Pennsylvania, USA. April 10-14, 1999. American Association for Cancer Research.
ISSN: 0197-016X.
CUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
NGUAGE: English
TRY DATE: Entered STN: 5 May 1999
Last Updated on STN: 5 May 1999
Human ***cytomegalovirus*** -activated ***calpain*** and p21Cip1 degradation in human lung fibroblasts.
Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1999) Vol. 40, pp. 447-448. print.
Meeting Info.: 90th Annual Meeting of the American Association for Cancer Research. Philadelphia, Pennsylvania, USA. April 10-14, 1999. American Association for Cancer Research.
ISSN: 0197-016X.
Major Concepts
Tumor Biology
Parts, Structures, & Systems of Organisms
lung fibroblasts
Chemicals & Biochemicals
calpain ; p21-Cip1: degradation
GN Classifier
Herpesviridae 03115
Super Taxa
dsDNA Viruses; Viruses; Microorganisms
Organism Name
human ***cytomegalovirus*** : pathogen
Taxa Notes
Double-Stranded DNA Viruses, Microorganisms, Viruses
GN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism. . .
78990-62-2 (***calpain***)

ANSWER 26 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
CESSION NUMBER: 1993:407472 BIOSIS
CUMENT NUMBER: PREV199396073197
TLE: Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors.
THOR(S): Molla, Akhteruzzaman; Hellen, Christopher U. T.; Wimmer, Eckard [Reprint author]
RPORATE SOURCE: Dep. Microbiol., Sch. Med., State Univ. New York at Stony Brook, Stony Brook, NY 11794-8621, USA
URCE: Journal of Virology, (1993) Vol. 67, No. 8, pp. 4688-4695.

MENT TYPE: Article
UAGE: English
Y DATE: Entered STN: 8 Sep 1993
Last Updated on STN: 6 Nov 1993
Journal of Virology, (1993) Vol. 67, No. 8, pp. 4688-4695.
CODEN: JOVIAM. ISSN: 0022-538X.
. . was unchanged, an observation suggesting that this inhibitor may have formed a covalent bond with the active-site Cys-109 nucleophile. Iodoacetamide, ***calpain*** inhibitor 1, and antipain inhibited poliovirus 2A-pro. MPCMK caused a reduction in the yields of the enteroviruses poliovirus type 1. . .
Major Concepts
Enzymology (Biochemistry and Molecular Biophysics); Microbiology; Pharmacology
Chemicals & Biochemicals
PROTEINASES; ELASTASE; ELASTATINAL; IODOACETAMIDE; ***CALPAIN*** ; ANTIPAIN
Miscellaneous Descriptors
CORNEAL INFLAMMATION; GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR; ***HERPES*** ***SIMPLEX*** VIRUS-TYPE I; INTERLEUKIN-1-ALPHA; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6
9001-92-7D (PROTEINASES)
9004-06-2 (ELASTASE)
51798-45-9 (ELASTATINAL)
144-48-9 (IODOACETAMIDE)
78990-62-2 (***CALPAIN***)
37691-11-5 (ANTIPAIN)

Logging off of STN---

cuting the logoff script...

LOG Y

IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
ESTIMATED COST	176.82	177.24
COUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
SUBSCRIBER PRICE	-2.77	-2.77

INTERNATIONAL LOGOFF AT 13:39:02 ON 08 JUN 2004